Gilead Sciences, Inc. (ETR: GIS)

Germany flag Germany · Delayed Price · Currency is EUR
88.94
+1.26 (1.44%)
Dec 20, 2024, 5:35 PM CET
22.51%
Market Cap 110.75B
Revenue (ttm) 25.37B
Net Income (ttm) 112.97M
Shares Out n/a
EPS (ttm) 0.09
PE Ratio 980.35
Forward PE n/a
Dividend 2.85 (3.21%)
Ex-Dividend Date Dec 13, 2024
Volume 873
Open 87.48
Previous Close 87.68
Day's Range 86.88 - 89.02
52-Week Range 57.29 - 92.80
Beta 0.20
Analysts n/a
Price Target n/a
Earnings Date Feb 3, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 18,000
Stock Exchange Deutsche Börse Xetra
Ticker Symbol GIS
Full Company Profile

Financial Performance

In 2023, Gilead Sciences's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.

Financial numbers in USD Financial Statements

News

Gilead Sciences Inc (GILD) to Present at J.P. Morgan Healthcare Conference

Gilead Sciences Inc (GILD) to Present at J.P. Morgan Healthcare Conference

17 hours ago - GuruFocus

Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning ...

18 hours ago - Wallstreet:Online

Gilead Sciences to Present at Upcoming Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Con...

18 hours ago - Business Wire

(GILD) - Analyzing Gilead Sciences's Short Interest

Gilead Sciences's (NYSE: GILD) short percent of float has risen 29.66% since its last report. The company recently reported that it has 23.41 million shares sold short , which is 1.88% of all regular...

1 day ago - Benzinga

Gilead raises Assembly Bio stake to ~30%

2 days ago - Seeking Alpha

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed addi...

2 days ago - Wallstreet:Online

Lightning Round: Uber is attractive at these levels, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stock including: Oracle, Gilead Sciences, Core Scientific, and Uber.

2 days ago - CNBC

Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD)

Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD)

2 days ago - GuruFocus

Gilead, Terray to collaborate on small molecule drugs

Gilead Sciences (GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small molecule therapeutics. Read more here.

3 days ago - Seeking Alpha

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (s...

4 days ago - Business Wire

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapie...

4 days ago - Wallstreet:Online

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to...

4 days ago - Business Wire

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc...

7 days ago - Benzinga

Gilead Sciences Inc (GILD) Receives Positive CHMP Opinion for Seladelpar in Treating Primary ...

Gilead Sciences Inc (GILD) Receives Positive CHMP Opinion for Seladelpar in Treating Primary Biliary Cholangitis

8 days ago - GuruFocus

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending selad...

8 days ago - Wallstreet:Online

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted...

8 days ago - Business Wire

Gilead appoints Dietmar Berger as Chief Medical Officer

Gilead (GILD) has announced the appointment of Dietmar Berger to succeed Merdad Parsey as Chief Medical Officer, effective January 2, 2025. Most recently, Berger was the Chief Medical Office

8 days ago - Seeking Alpha

Gilead Sciences Appoints New Chief Medical Officer to Strengthen Leadership in Virology and Oncology

Gilead Sciences Appoints New Chief Medical Officer to Strengthen Leadership in Virology and Oncology

8 days ago - GuruFocus

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.

8 days ago - Reuters

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leader...

8 days ago - Wallstreet:Online

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will bec...

8 days ago - Business Wire

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ: GILD) revealed that it is developing a once-yearly injectable formulation for lenacapavir. The annual formulation is curr...

8 days ago - Benzinga